Author:
Buzhdygan Tetyana P.,Rodrigues Cassidy R.,McGary Hannah M.,Khan Jana A.,Andrews Allison M.,Rawls Scott M.,Ramirez Servio H.
Abstract
AbstractBackgroundSynthetic cathinones are a category of psychostimulants belonging to the growing number of designer drugs also known as “Novel Psychoactive Substances” (NPS). In recent years, NPS have gained popularity in the recreational drug market due to their amphetamine-like stimulant effects, low cost, ease of availability, and lack of detection by conventional toxicology screening. All these factors have led to an increase in NPS substance abuse among the young adults, followed by spike of overdose-related fatalities and adverse effects, severe neurotoxicity, and cerebral vascular complications. Much remains unknown about how synthetic cathinones negatively affect the CNS and the status of the blood-brain barrier (BBB).MethodsWe used in vitro models of the BBB and primary human brain microvascular endothelial cells (hBMVEC) to investigate the effects of the synthetic cathinone, 4-methyl methcathinone (mephedrone), on BBB properties.ResultsWe showed that mephedrone exposure resulted in the loss of barrier properties and endothelial dysfunction of primary hBMVEC. Increased permeability and decreased transendothelial electrical resistance of the endothelial barrier were attributed to changes in key proteins involved in the tight junction formation. Elevated expression of matrix metalloproteinases, angiogenic growth factors, and inflammatory cytokines can be explained by TLR-4-dependent activation of NF-κB signaling.ConclusionsIn this first characterization of the effects of a synthetic cathinone on human brain endothelial cells, it appears clear that mephedrone-induced damage of the BBB is not limited by the disruption of the barrier properties but also include endothelial activation and inflammation. This may especially be important in comorbid situations of mephedrone abuse and HIV-1 infections. In this context, mephedrone could negatively affect HIV-1 neuroinvasion and NeuroAIDS progression.
Funder
National Institute on Drug Abuse
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology,Immunology,General Neuroscience
Reference59 articles.
1. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther. 2011;339(2):530–6.
2. Allen-Campbell S, Oakes H, Hanley A, Pond B. Dopamine toxicity following chronic co-exposure to ‘Bath Salt’ constituents MDPV, mephedrone, and methylone. Faseb J. 2017;31:987.
3. Anneken JH, Angoa-Perez M, Sati GC, Crich D, Kuhn DM. Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine. Neuropharmacology. 2018;134:46–56.
4. King MV, Shortall SE, Green AR, Fone KCF. Contribution of 5-HT and dopamine to the physiological and behavioural effects of mephedrone following binge dosing in the rat. Eur Neuropsychopharm. 2014;24:S217–S8.
5. Papaseit E, Perez-Mana C, Mateus JA, Pujadas M, Fonseca F, Torrens M, et al. Human pharmacology of mephedrone in comparison with MDMA. Neuropsychopharmacol. 2016;41(11):2704–13.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献